Crospon Completes First Shipment To Europe; Endoflip Now In Commercial Production
Following the announcement of a worldwide distribution deal in May with Dutch company, Medical Measurement Systems, Crospon has completed its start-up activities for EndoFLIP® and has now gone into commercial production.
Crospon develops leading edge minimally invasive medical devices for monitoring, diagnosis and therapy in the gastroenterology area.
Announcing the completion of the first shipment, John O’Dea, CEO, Crospon said, “The shipment marks a real milestone both Crospon and EndoFLIP®. We as a team at Crospon have been working towards this target for the last two years. I would like to take this opportunity to thank all of the staff at Crospon who have each played an integral part in bringing the company to this point. We look forward taking to the next steps in extending the application of the EndoFLIP® platform technology into the Bariatric Surgery marketplace in the coming year.”
The EndoFLIP® tool which is pending FDA approval was designed by Crospon to provide a more physiologically relevant diagnostic test for gastroesophageal reflux disease (GERD). Chronic GERD is a prevalent disorder reaching epidemic proportions worldwide that manifests itself as severe heartburn caused by stomach acid refluxing up into the oesophagus.
Crospon’s development of the EndoFLIP® system was recently recognised with the 2009 European Gastroenterology Technology Implementation of the Year Award, by Frost & Sullivan.
In January, Crospon announced that its EndoFLIP® system had received CE Mark certification from the NSAI (National Standards Authority of Ireland), the Irish notified body in accordance with the European Medical Device Directive. The Company also announced the appointment of Larry Fulton as Vice President of Sales –Americas located at the Crospon’s newly established US operation in Carlsbad, California.
About Crospon
Established in 2006, Crospon is a medical device company focused on the monitoring and treatment of gastroesophageal reflux disorder (GERD). Company co-founder and CEO, John O’Dea, previously co-founded Caradyne, a respiratory products company which was acquired by Respironics Inc in 2004.
In 2008, Crospon announced that it had completed an additional funding round of €3.5m. This funding will be primarily used for the completion of development, manufacturing start-up and preparation to market of the EndoFLIP®system.
Crospon was awarded the Connaught Business Achievers Award for 2008 in the ‘Ones to Watch’ category and the company’s Smart Drug Delivery Patch in conjunction with HP was listed in Popular Science’s magazines annual ‘Best of What’s New’ for 2008.